Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration

IF 2.8 Q1 OPHTHALMOLOGY Ophthalmology. Glaucoma Pub Date : 2024-05-01 DOI:10.1016/j.ogla.2024.01.002
Adam L. Rothman MD , Flavius A. Beca MD , Jonathan D. Tijerina MD , Darren M. Schuman BS , Richard K. Parrish II MD , Elizabeth A. Vanner PhD , Katy C. Liu MD, PhD
{"title":"Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration","authors":"Adam L. Rothman MD ,&nbsp;Flavius A. Beca MD ,&nbsp;Jonathan D. Tijerina MD ,&nbsp;Darren M. Schuman BS ,&nbsp;Richard K. Parrish II MD ,&nbsp;Elizabeth A. Vanner PhD ,&nbsp;Katy C. Liu MD, PhD","doi":"10.1016/j.ogla.2024.01.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF.</p></div><div><h3>Design</h3><p>Retrospective clinical cohort study.</p></div><div><h3>Participants</h3><p>Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded.</p></div><div><h3>Methods</h3><p>A Kaplan–Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) &gt; 21 mmHg or &lt; 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP &gt; 21 mmHg within 3 months of surgery after a reduction to &lt; 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (&lt; 1 year) and late (&gt; 1 year) complications were compared through 5 years.</p></div><div><h3>Main Outcome Measures</h3><p>Survival analysis, IOP, number of medications.</p></div><div><h3>Results</h3><p>Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (<em>P</em> = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (<em>P</em> = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, <em>P</em> = 0.05), greater IOP reduction (60% vs. 49%, <em>P</em> = 0.04), fewer medications (1.2 vs. 2.1, <em>P</em> = 0.02), and more complete success (50% vs. 15%, <em>P</em> = 0.001) at final follow-up (32 vs. 36 months, <em>P</em> = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], <em>P</em> = 0.04). There were no significant differences in early or late complications.</p></div><div><h3>Conclusions</h3><p>Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery.</p></div><div><h3>Financial Disclosure(s)</h3><p>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589419624000103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF.

Design

Retrospective clinical cohort study.

Participants

Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded.

Methods

A Kaplan–Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) > 21 mmHg or < 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP > 21 mmHg within 3 months of surgery after a reduction to < 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (< 1 year) and late (> 1 year) complications were compared through 5 years.

Main Outcome Measures

Survival analysis, IOP, number of medications.

Results

Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (P = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (P = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, P = 0.05), greater IOP reduction (60% vs. 49%, P = 0.04), fewer medications (1.2 vs. 2.1, P = 0.02), and more complete success (50% vs. 15%, P = 0.001) at final follow-up (32 vs. 36 months, P = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], P = 0.04). There were no significant differences in early or late complications.

Conclusions

Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年性黄斑变性患者使用和不使用抗血管内皮生长因子的青光眼导管疗效。
目的:比较注射抗血管内皮生长因子(VEGF)的湿性年龄相关性黄斑变性(AMD)眼球与未注射抗血管内皮生长因子的干性AMD眼球的青光眼导管疗效:回顾性临床队列研究:湿性老年性黄斑病变患者,术前一年内或独立青光眼导管手术后曾接受过抗血管内皮生长因子治疗;干性老年性黄斑病变患者,随访至少 6 个月,无抗血管内皮生长因子治疗史。不包括新生血管性青光眼或因湿性AMD以外原因抗VEGF的眼球:卡普兰-梅耶分析比较了湿性和干性 AMD 患者的存活率。失败的定义是眼压(IOP)>21 mmHg,或手术后三个月内眼压(IOP)>21 mmHg,且手术后眼压(IOP)降低至1年)并发症的发生时间为五年:结果:湿性AMD眼(24只)和干性AMD眼(54只)的基线眼压、用药次数或导管类型无显著差异。没有湿性 AMD 眼睛失败,而干性 AMD 眼睛有 10 只(18%)失败(P=0.03)。湿性 AMD 的五年存活率估计为 100%,干性 AMD 为 72%(P=0.04)。湿性 AMD 患者的眼压较低(10.6 mmHg 对 12.7 mmHg,P=0.05),眼压降低幅度较大(60% 对 49%,P=0.04),用药较少(1.2 对 2.1,P=0.02),最终随访时(32 个月对 36 个月,P=0.42)完全成功的比例较高(50% 对 15%,P=0.001)。出现高血压期的湿性 AMD 眼睛比干性 AMD 眼睛少(0/10(0%)对 4/10(40%),P=0.04)。早期或晚期并发症无明显差异:抗血管内皮生长因子可能会影响术后伤口愈合和囊的形成,从而改善青光眼导管手术的效果。考虑在青光眼导管手术围手术期使用抗血管内皮生长因子需要前瞻性数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ophthalmology. Glaucoma
Ophthalmology. Glaucoma OPHTHALMOLOGY-
CiteScore
4.80
自引率
6.90%
发文量
140
审稿时长
46 days
期刊最新文献
Contents Editorial Board Advanced Imaging in Traumatic Glaucoma: Detection of Intralenticular Foreign Body Starstruck Lens: Iatrogenic Rosette Cataract and Its Spontaneous Resolution Unusual Posterior Capsular Pigmentation in Axenfeld–Rieger Anomaly
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1